Published in PLoS One on February 19, 2013
Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review. Metabolomics (2014) 1.24
Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality. EMBO Mol Med (2015) 1.07
Metabolomics of the tumor microenvironment in pediatric acute lymphoblastic leukemia. PLoS One (2013) 1.01
The future of NMR metabolomics in cancer therapy: towards personalizing treatment and developing targeted drugs? Metabolites (2013) 0.81
A dried blood spot mass spectrometry metabolomic approach for rapid breast cancer detection. Onco Targets Ther (2016) 0.79
Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiple myeloma. Blood Cancer J (2015) 0.79
Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis. RMD Open (2016) 0.75
Monitoring cancer prognosis, diagnosis and treatment efficacy using metabolomics and lipidomics. Metabolomics (2016) 0.75
Biofluid metabotyping of occupationally exposed subjects to air pollution demonstrates high oxidative stress and deregulated amino acid metabolism. Sci Rep (2016) 0.75
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Multiple myeloma. N Engl J Med (2011) 10.38
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer (2007) 10.20
Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc (2007) 5.92
Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. Anal Chem (2006) 4.29
alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS One (2010) 2.94
Metabolic phenotyping in health and disease. Cell (2008) 2.80
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood (2011) 2.69
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Treatment of multiple myeloma. Nat Rev Clin Oncol (2011) 2.46
Pathogenesis of myeloma bone disease. Leukemia (2008) 2.04
NMRLAB-Advanced NMR data processing in matlab J Magn Reson (2000) 1.96
Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer (2005) 1.84
Application of chemometrics to 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. Analyst (2003) 1.65
Molecular enzymology of carnitine transfer and transport. Biochim Biophys Acta (2001) 1.53
Optimized metabolite extraction from blood serum for 1H nuclear magnetic resonance spectroscopy. Anal Biochem (2008) 1.51
Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. Neoplasia (2009) 1.50
Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev (2010) 1.48
Comprehensive two-dimensional gas chromatography/time-of-flight mass spectrometry for metabonomics: Biomarker discovery for diabetes mellitus. Anal Chim Acta (2008) 1.43
Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. Leukemia (2010) 1.41
Improved classification accuracy in 1- and 2-dimensional NMR metabolomics data using the variance stabilising generalised logarithm transformation. BMC Bioinformatics (2007) 1.41
High-throughput 1H NMR-based metabolic analysis of human serum and urine for large-scale epidemiological studies: validation study. Int J Epidemiol (2008) 1.39
Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells. Cancer Res (2006) 1.35
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood (2011) 1.32
Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure. Am J Physiol Renal Physiol (2000) 1.27
The role of carnitine in normal and altered fatty acid metabolism. Am J Kidney Dis (2003) 1.25
Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol (2011) 1.20
Metabonomic profiling of renal cell carcinoma: high-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis. Anal Chim Acta (2008) 1.14
Killing tumours by ceramide-induced apoptosis: a critique of available drugs. Biochem J (2003) 1.06
Fast targeted multidimensional NMR metabolomics of colorectal cancer. Magn Reson Chem (2009) 0.96
Metabolic approaches to treatment of melanoma. Clin Cancer Res (2009) 0.95
The microenvironment and molecular biology of the multiple myeloma tumor. Adv Cancer Res (2011) 0.94
Detection of urinary drug metabolite (xenometabolome) signatures in molecular epidemiology studies via statistical total correlation (NMR) spectroscopy. Anal Chem (2007) 0.93
Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica (2009) 0.93
Carnitine: metabolism and clinical chemistry. Clin Chim Acta (1989) 0.86
High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later. J Clin Oncol (2008) 0.85
Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunities. Semin Hematol (2011) 0.85
L-carnitine modifies the humoral immune response in mice after in vitro or in vivo treatment. Int Immunopharmacol (2001) 0.85
Chemotherapy-associated changes in 31P MRS spectra of sera from patients with multiple myeloma. NMR Biomed (1995) 0.83
L-carnitine protects against apoptosis of murine MC3T3-E1 osteoblastic cells. Amino Acids (2007) 0.83
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Curr Hematol Malig Rep (2010) 0.82
Metabolic characterization of a hyper-productive state in an antibody producing NS0 myeloma cell line. Metab Eng (2009) 0.82
L-carnitine and isovaleryl L-carnitine fumarate positively affect human osteoblast proliferation and differentiation in vitro. Calcif Tissue Int (2005) 0.81
Iron chelation therapy in Upper Egyptian transfusion-dependent pediatric homozygous beta-thalassemia major: impact on serum L-carnitine/free fatty acids, osteoprotegerin/the soluble receptor activator of nuclear factor-kappabeta ligand systems, and bone mineral density. J Pediatr Hematol Oncol (2010) 0.80
Ceramide induces apoptosis via a peroxisome proliferator-activated receptor gamma-dependent pathway. Apoptosis (2006) 0.80
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med (2003) 8.93
Proposed minimum reporting standards for chemical analysis Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics (2007) 6.93
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet (2010) 5.04
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol (2013) 3.75
Serum test for assessment of patients with Bence Jones myeloma. Lancet (2003) 3.04
Dysregulated humoral immunity to nontyphoidal Salmonella in HIV-infected African adults. Science (2010) 2.91
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood (2011) 2.69
IgM myeloma: a rare entity characterized by a CD20-CD56-CD117- immunophenotype and the t(11;14). Br J Haematol (2008) 2.54
Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology (2004) 2.51
Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells. Cell Metab (2012) 2.43
Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood (2006) 2.43
Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood (2007) 2.38
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood (2012) 2.38
The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children. J Clin Invest (2008) 2.35
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood (2010) 2.25
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood (2003) 2.23
Optimizing protein stability in vivo. Mol Cell (2009) 2.15
Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. Clin Chem (2009) 1.99
Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. J Clin Oncol (2005) 1.97
High-throughput tissue extraction protocol for NMR- and MS-based metabolomics. Anal Biochem (2007) 1.97
Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood (2002) 1.95
Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant (2005) 1.87
RIDDLE immunodeficiency syndrome is linked to defects in 53BP1-mediated DNA damage signaling. Proc Natl Acad Sci U S A (2007) 1.79
The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma (2009) 1.77
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol (2011) 1.71
Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol (2011) 1.71
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res (2007) 1.70
Importance of antibody and complement for oxidative burst and killing of invasive nontyphoidal Salmonella by blood cells in Africans. Proc Natl Acad Sci U S A (2010) 1.68
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood (2010) 1.67
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol (2011) 1.66
Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response. EMBO J (2011) 1.65
Polymorphisms in the oxidative stress genes, superoxide dismutase, glutathione peroxidase and catalase and risk of non-Hodgkin's lymphoma. Haematologica (2006) 1.64
Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood (2013) 1.64
Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma. Radiology (2014) 1.64
The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. Clin Cancer Res (2011) 1.61
Gastric marginal zone lymphoma is associated with polymorphisms in genes involved in inflammatory response and antioxidative capacity. Blood (2003) 1.60
High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leuk Lymphoma (2010) 1.58
Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res (2003) 1.53
Discovery of metabolic signatures for predicting whole organism toxicology. Toxicol Sci (2010) 1.52
Optimized metabolite extraction from blood serum for 1H nuclear magnetic resonance spectroscopy. Anal Biochem (2008) 1.51
Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. Neoplasia (2009) 1.50
Insight into the molecular pathogenesis of hairy cell leukaemia, hairy cell leukaemia variant and splenic marginal zone lymphoma, provided by the analysis of their IGH rearrangements and somatic hypermutation patterns. Br J Haematol (2009) 1.48
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood (2008) 1.45
Structure and function of BamE within the outer membrane and the β-barrel assembly machine. EMBO Rep (2011) 1.45
Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res (2011) 1.44
Improved classification accuracy in 1- and 2-dimensional NMR metabolomics data using the variance stabilising generalised logarithm transformation. BMC Bioinformatics (2007) 1.41
Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin. Cancer Res (2004) 1.40
Self-expanding stent implantation in arterial duct during hybrid palliation of hypoplastic left heart syndrome: midterm experience with a specially designed stent. EuroIntervention (2015) 1.39
Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin Cancer Res (2010) 1.39
XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood (2010) 1.36
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood (2013) 1.35
Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway. Cell Metab (2012) 1.35
Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood (2002) 1.34
A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood (2012) 1.33
How I treat monoclonal gammopathy of renal significance (MGRS). Blood (2013) 1.33
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood (2011) 1.32
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica (2011) 1.32
Untangling the unfolded protein response. Cell Cycle (2008) 1.32
The role of reporting standards for metabolite annotation and identification in metabolomic studies. Gigascience (2013) 1.31
Slug regulates integrin expression and cell proliferation in human epidermal keratinocytes. J Biol Chem (2006) 1.30
Spectral relative standard deviation: a practical benchmark in metabolomics. Analyst (2008) 1.30
PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood (2005) 1.29
Metabolomic profiling of drug responses in acute myeloid leukaemia cell lines. PLoS One (2009) 1.28
MetaboLab--advanced NMR data processing and analysis for metabolomics. BMC Bioinformatics (2011) 1.27
Effects of temperature on host-pathogen-drug interactions in red abalone, Haliotis rufescens, determined by 1H NMR metabolomics. Environ Sci Technol (2006) 1.25
Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood (2002) 1.22
Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma. Ther Clin Risk Manag (2006) 1.20
MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica (2008) 1.20
Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res (2008) 1.19
Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem (2002) 1.18
Direct sampling of organisms from the field and knowledge of their phenotype: key recommendations for environmental metabolomics. Environ Sci Technol (2007) 1.18
Two-dimensional J-resolved NMR spectroscopy: review of a key methodology in the metabolomics toolbox. Phytochem Anal (2009) 1.18
The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res (2003) 1.17
A signal filtering method for improved quantification and noise discrimination in fourier transform ion cyclotron resonance mass spectrometry-based metabolomics data. J Am Soc Mass Spectrom (2009) 1.17
Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood (2013) 1.16
Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab. Eur J Immunol (2008) 1.14
Epigenetic consequences of AML1-ETO action at the human c-FMS locus. EMBO J (2003) 1.14
Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood (2007) 1.11
Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res (2013) 1.11
NMR-based metabolomic analysis of cerebrospinal fluid and serum in neurological diseases--a diagnostic tool? NMR Biomed (2010) 1.10
Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol (2002) 1.09
Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood (2004) 1.09
Finger-prick blood samples can be used interchangeably with venous samples for CD4 cell counting indicating their potential for use in CD4 rapid tests. AIDS (2007) 1.08
The serotonin transporter (SLC6A4) is present in B-cell clones of diverse malignant origin: probing a potential anti-tumor target for psychotropics. FASEB J (2005) 1.07